|
Diabetes Mellitus, Insulin-Dependent
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Vital capacity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study is aimed to test if SENP1 regulates the glycolysis of prostate cancer cells (CaP) by improving stability of HIF1α protein.
|
30745829 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SENP1, a member of this family, is highly expressed and plays oncogenic roles in diverse cancers including prostate cancer.
|
29705808 |
2018 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Dysregulation of SUMO-specific protease 1 (SENP1) expression has been reported in several kinds of cancer, including human colorectal and prostate cancers, proposing SENP1 as an oncogene with a critical role in cancer progression. miR-133a-3p has been reported as a tumor suppressor in several malignant neoplasias.
|
28748780 |
2018 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
SENP1 regulates PTEN stability to dictate prostate cancer development.
|
27852060 |
2017 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study we analyzed prevalence and prognostic impact of the de-SUMOylation enzyme SENP1 in prostate cancer.
|
26202067 |
2015 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we found that low expression of miR-145 was correlated with high expression of SENP1 in PCa cell line PC-3.
|
25645686 |
2015 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.
|
22733136 |
2013 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive SENP1 immunostaining in the CaP, PIN, and normal prostate tissue samples were 76.5%, 57.9%, and 4.2%, respectively.
|
23089540 |
2013 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
SUMO-specific protease 1 (SENP1) was thought to be a potential marker and therapeutical target of PCa.
|
22666381 |
2012 |
|
Corpuscular Hemoglobin Concentration Mean
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Seventy-five genetic loci influencing the human red blood cell.
|
23222517 |
2012 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that SENP1 (sentrin/SUMO-specific protease 1) is highly expressed in human prostate cancer specimens and correlates with hypoxia-inducing factor 1alpha (HIF1alpha) expression.
|
20551310 |
2010 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The expression of SENP1 mRNA was significantly increased in human prostatic carcinoma cell lines after exposure to hypoxia, accompanied by the up-regulation of HIF1α.
|
30745829 |
2019 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
SENP1, a member of this family, is highly expressed and plays oncogenic roles in diverse cancers including prostate cancer.
|
29705808 |
2018 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
SENP1 regulates PTEN stability to dictate prostate cancer development.
|
27852060 |
2017 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In the current study we analyzed prevalence and prognostic impact of the de-SUMOylation enzyme SENP1 in prostate cancer.
|
26202067 |
2015 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here we found that low expression of miR-145 was correlated with high expression of SENP1 in PCa cell line PC-3.
|
25645686 |
2015 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
All these results show the contribution of SENP1 to the progression of prostate cancer, and suggest that SENP1 may be a prognostic marker and a therapeutic target for metastasis in prostate cancer patients.
|
22733136 |
2013 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Positive SENP1 immunostaining in the CaP, PIN, and normal prostate tissue samples were 76.5%, 57.9%, and 4.2%, respectively.
|
23089540 |
2013 |
|
Prostate carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
SUMO-specific protease 1 (SENP1) was thought to be a potential marker and therapeutical target of PCa.
|
22666381 |
2012 |
|
Prostate carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that SENP1 (sentrin/SUMO-specific protease 1) is highly expressed in human prostate cancer specimens and correlates with hypoxia-inducing factor 1alpha (HIF1alpha) expression.
|
20551310 |
2010 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The up-regulation of SENP1 promotes tumor cell proliferation and tumorgenesis by interacting with HIF1α which was deSUMOylated and sequentially leading to a "Warburg effect".
|
30745829 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Dysregulation of SUMO-specific protease 1 (SENP1) expression has been reported in several kinds of cancer, including human colorectal and prostate cancers, proposing SENP1 as an oncogene with a critical role in cancer progression. miR-133a-3p has been reported as a tumor suppressor in several malignant neoplasias.
|
28748780 |
2018 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
This study was to investigate the association of SENP1 with resistance of NSCLC tumor to chemoradiotherapy.
|
30043429 |
2018 |